←
Jay Pandit119 posts
Jay Pandit avatar

Jay Pandit

@JayPandit

Director of Digital Medicine, Scripps Research, NU Cardiology, Physician Entrepreneur, Cancer Survivor, Story Banker and Life Long Learner. Views are my own.

◷ Joined October 2009▧ 4 Photos and videos
Jay Pandit avatar
Jay Pandit@JayPandit·May 9

The FDA isn’t issuing one-off wearable clearances any more - it’s building a regulatory architecture for continuous diagnostic surveillance. Cardiac, metabolic, neurodx, and RPM all moving in parallel. Medicine needs to catch up fast. #DigitalHealth #FDAclearance #ClinicalAI

Eric Topol avatar
⟳ Jay Pandit retweeted
Eric Topol@EricTopol·31 Jul 2025

Our @NatureMedicine paper on glucose spikes (CGM sensor) and their relationship with physical activity, gut microbiome, genomics, food intake, and sleep via multimodal A.I. Helps identify people with prediabetes who have high risk of progression (cf HbA1c) nature.com/articles/s41591-0… @GiorgioQuer @ScrippsRTI @scrippsresearch @segal_eran @JayPandit

Jay Pandit avatar
Jay Pandit@JayPandit·28 Feb 2024

Acute care at home has all the ingredients to improve health care outcomes and costs and is the ideal place to test the impact of multimodal inpatient and outpatient health data streams. Let’s do the trials to show this! nature.com/articles/s41746-0…

Eric Topol avatar
⟳ Jay Pandit retweeted
Eric Topol@EricTopol·24 Feb 2023

Just published A prospective, systematic assessment of rebound after Paxlovid vs Covid untreated controls academic.oup.com/cid/advance… @JayPandit @michaelmina_lab Viral rebound Paxlovid 14.2% | Controls 9.3% Symptom rebound Paxlovid 18.9% | Controls 7.0%

Jay Pandit avatar
Jay Pandit@JayPandit·16 Nov 2022

First report of our prospective paxlovid rebound study showing rebound of Covid sx more than previously reported, in both treated and untreated cohorts. More studies needed to understand this peculiar phenomenon, to clear myths causing underprescription.

Eric Topol@EricTopol15 Nov 2022

Our prospective Paxlovid rebound study with controls preprint is posted By symptoms: ~12% rebound (19% Pax vs 7% controls) By positive testing: ~5% rebound (14% Pax vs 9% controls) Much lower than many estimates medrxiv.org/content/10.1101/… by @JayPandit @michaelmina_lab @ScrippsRTI

Jay Pandit avatar
Jay Pandit@JayPandit·20 Jun 2022

Digital health tools like smartphone apps and wearables are here to stay. We hope our work sheds light on the promises and challenges of their power to serve as supplementary population health tools. @ScrippsDTC @scrippsresearch @NUFeinbergMed

Eric Topol@EricTopol20 Jun 2022

Just published @NatureBiotech Our review of smartphone apps for Covid-19: outbreak epidemiology, individual screening, contact tracing and their future by @JayPandit @jmradin @GiorgioQuer @ScrippsRTI @scrippsresearch nature.com/articles/s41587-0…

Post attachmentPost attachmentPost attachmentPost attachment